Australia’s National Health and Medical Research Council opened public consultation on draft puberty-suppressant advice on 16 November 2026, releasing supporting evidence for scrutiny. The consultation gives researchers, universities and professional organisations a route to comment on evidence interpretation and guideline development before broader national guidance for trans and gender diverse people aged under 18 is completed.
NHMRC releases advice and supporting reports
The NHMRC announcement says the Australian Government requested national clinical practice guidelines and made advice on puberty suppressants a priority. The agency has released that advice for consultation alongside an evidence evaluation report, technical report and administrative report.
NHMRC says development combines systematic assessment of scientific evidence, expert judgement and the perspectives of people affected by the guidance. Its invitation explicitly includes researchers and professional organisations, alongside young people, families and clinicians. That makes the release an opportunity to examine both the underlying research and the reasoning used to turn it into proposed advice.
How the draft moves from evidence to advice
The 45-page November consultation draft contains a conditional recommendation and good practice statements. These remain proposals within an ongoing guideline process. The document describes the use of GRADE, the Grading of Recommendations, Assessment, Development and Evaluation approach, and its Evidence-to-Decision framework.
The draft explains that conditional recommendations can reflect the importance of individual preferences and low overall certainty in the available evidence; it identifies both considerations here. A recommendation’s strength and an evidence-certainty assessment therefore answer different questions. The supporting Evidence-to-Decision framework provides the bridge between assessment and a committee’s judgement.
The Gender Guidelines Development Committee includes people with experience of accessing care as young people or supporting a young person as a parent or carer. The draft also describes input from a reference panel involving lived experience, clinicians and researchers. It says critical and important outcomes relevant to affected young people and their parents or carers were prioritised for review.
A commissioned review with an October report date
The 81-page Evidence Evaluation Report is dated 17 October 2026. Its authors are Sue Brennan and colleagues from Cochrane Australia and the Methods in Evidence Synthesis Unit at Monash University. The report records an October 2025 commission and NHMRC approval of its protocol in March 2026. Those dates describe the work behind the November consultation.
The authors leave implications for clinical practice to the guideline committee. Their research discussion instead identifies appropriate comparator groups, control of confounding and better outcome reporting as priorities. It also highlights research on which outcomes matter most to young people and the potential contribution of core outcome sets. These are specific methodological issues for researchers working with observational study designs.
The report notes that separately reporting data relevant to puberty suppression could make primary studies more useful for synthesis. This gives university research teams a concrete issue to examine when commenting on how existing evidence has been assembled and interpreted, rather than treating the consultation solely as a response to a recommendation.
College response and state policy reactions
In its 16 November response, the Royal Australian and New Zealand College of Psychiatrists said expert committees were reviewing the interim advice and that the College would contribute to consultation. President Dr Astha Tomar supported further high-quality research and long-term monitoring of outcomes. She also argued that uncertainty should not automatically produce blanket restrictions on access to care. That is the College’s policy position as a participating stakeholder.
ABC’s reporting on 16 November described the advice as advisory rather than legally mandatory. It reported that Queensland Health Minister Tim Nicholls and a Northern Territory government spokesperson said their positions remained unchanged. Federal Health Minister Mark Butler said he expected states and territories to consider the advice. The consultation’s opening therefore does not itself change those jurisdictions’ policies.
What university submissions can address
For research offices coordinating an institutional response, a useful approach is to separate comments on evidence interpretation, committee reasoning and implementation. Methodologists can identify the precise assessment they contest or support; clinical research teams and lived-experience contributors can address whether the proposed advice reflects relevant outcomes and practical considerations. This structure would connect the university’s technical evidence comments with its assessment of implementation.
The official consultation notice directs submissions through NHMRC’s Consultation Hub. It specifies 500-word limits for responses about the advice and a 1,000-word allowance for other comments. Respondents need not answer every question, and the notice says documents cannot be uploaded. Institutions preparing detailed critiques can therefore plan concise, self-contained responses.
Consultation closes on 18 January 2027
The deadline is 13:00 AEDT on 18 January 2027. NHMRC says feedback will inform development of the full national guidelines. This is the first of two consultation opportunities, with the full guidelines due for consultation by early 2028. Universities preparing submissions have a defined current deadline and a later opportunity to consider the broader guideline package.
Sources
- NHMRC: NHMRC releases advice on puberty suppressants for public consultation, 16 November 2026; checked 2026-11-17.
- NHMRC: Advice on the use of puberty suppressants in the care of trans and gender diverse people aged under 18 — consultation notice, checked 2026-11-17.
- NHMRC: Advice on the use of puberty suppressants in the care of trans and gender diverse people aged under 18 — consultation draft, November 2026; checked 2026-11-17.
- Brennan and colleagues, for NHMRC: Effects of puberty suppression in young people (under 18 years) experiencing gender incongruence or dysphoria: systematic review and meta-analysis, 17 October 2026; checked 2026-11-17.
- ABC News: Puberty blockers should remain an option for trans youth, new national advice finds, 16 November 2026; checked 2026-11-17.
- RANZCP: Response to new National Health and Medical Research Council guidelines on the care of trans and gender diverse people, 16 November 2026; checked 2026-11-17.







